| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA456: Ustekinumab for moderately to severely active Crohn's disease after previous treatment |
|
Medicine details |
|
| Medicine name | ustekinumab (Stelara®) |
| Formulation | subcutaneous injection |
| Reference number | 961 |
| Indication | Treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Gastro-intestinal system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 10/11/2016 |
| NICE guidance | TA456: Ustekinumab for moderately to severely active Crohn's disease after previous treatment |